For Boston Scientific, a potential threat
236748
Boston Scientific Corp. could face tougher competition in markets for cardiac products if talks between two of its largest competitors lead to a merger, analysts and investors said.
311263
Boston Scientific Corp. BSX.N, whose  Taxus heart device has been involved in a major recall, said on  Wednesday preliminary August sales of the device slowed to $200  million from $207 million reported in July, and issued an  outlook that was below Wall Street estimates.
519968
The field, expected to become a trillion-dollar industry by 2012, promises a host of technological and medical advances while also stirring fears because some of the products appear to be toxic and many are not regulated.
332843
NATICK, Mass. - Boston Scientific Corp. violated its agreement with an Israeli company and acted in &quot;bad faith&quot; when it set up a secret stent-making operation in Ireland, according to a federal judge who ordered the companies to reach a settlement.
663002
Scary drug-resistant bacteria are on the rise, but there are simple ways to avoid infection.
290938
Boston Scientific Corp. BSX.N on   Thursday said an internal analysis confirmed an increased risk   of blood clots with its drug-coated device used to keep   previously clogged arteries open.
316372
Employee-owned consumer devices used at work present a threat that security professionals must manage, analysts say.
85181
A medical researcher who testified at a House hearing about the safety of the popular diabetes drug, Avandia, said he received the veiled threat of a lawsuit by a high-ranking drug company executive.
284993
Doctors have been taking calls from anxious patients ever since a Senate hearing on Vioxx last week at which an FDA scientist expressed concerns about the safety of five other drugs on the market.
160526
Blog: Industry leaders are worried that evolving technology may be getting a bad rap.
723922
Don't buy without considering threat of entry, bargaining power, and more.
292756
Here's the real threat facing investors right now.
37904
The drug maker's difficulties are evident, but its productivity may make it worth a second look.
517635
It may be too early to tell, but some Symantec partners have already begun to express concern.
432255
A power failure with potentially devastating consequences at a new high-security research center provokes a critic's call for change.
188313
A contentious legal fight between Boston Scientific Corp. and a California subsidiary it bought in 2004 took a sharp twist this week when lawyers asked a judge to consider undoing the deal.
286546
A controversial nerve stimulator implant to treat severe forms of depression has a company on edge.